ORIC
ORIC Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ORIC
Oric Pharmaceuticals, Inc.
A clinical stage biopharmaceutical company that develops commercializes novel therapies to address the resistance in cancer
240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080
--
ORIC Pharmaceuticals, Inc., was incorporated in Delaware in August 2014. The company is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients by overcoming cancer resistance.
Company Financials
EPS
ORIC has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.4, beating expectations. The chart below visualizes how ORIC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
